Drug firm Wockhardt on Tuesday reported a consolidated net loss of Rs 177 crore for the fourth quarter ended March 31, 2024. The company had reported a net loss of Rs 237 crore in the January-March quarter of 2022-23.
Revenue from operations stood at Rs 700 crore for the period under review as compared with Rs 678 crore in the same period of FY23, the Mumbai-based drugmaker said in a regulatory filing.
For the year ended March 31, 2024, the company reported a net loss of Rs 472 crore against a net loss of Rs 621 crore in 2022-23 fiscal.
Revenue from operations increased to Rs 2,798 crore in FY24 compared with Rs 2,651 crore in FY23.
The company said its board approved the re-appointment of Habil Khorakiwala as Executive Chairman for a further term of five years with effect from March 1, 2025, to Feb. 28, 2030.
Shares of the company on Tuesday ended 0.49% down at Rs 557.95 apiece on the BSE.
RECOMMENDED FOR YOU

Wockhardt Rebounds From Friday's Slump; Stock Surges 9% — Here's Why


SpiceJet Shares Tumble Following Q1 Loss Of Rs 234 Crore

.jpg?rect=0%2C0%2C3500%2C1969&w=320)
JSW Cement Q1 Results: Net Loss Widens To Rs 1,356 Crore On Exceptional Expense

Wockhardt Q1 Results: Loss Widens To Rs 108 Crore
